Table 1.
Demographic and clinicopathological manifestations.
| Variables | All (n = 125) | Protruding (n = 77) | Ulcerative (n = 48) | P-value |
|---|---|---|---|---|
| Gender, n (%) | 0.97 | |||
| Male | 81 (64.8%) | 50 (64.9%) | 31 (64.6%) | |
| Female | 44 (35.2%) | 27 (35.1%) | 17 (35.4%) | |
| Age (yr, mean ± SD) | 56.1 ± 11.8 | 54.9 ± 11.0 | 58.0 ± 12.7 | 0.15 |
| BMI (kg/m2, mean ± SD) | 24.3 ± 3.0 | 24.6 ± 3.4 | 23.9 ± 3.0 | 0.29 |
| Family history of cancer, n (%) | 28 (22.4%) | 19 (25.0%) | 9 (18.8%) | 0.45 |
| Smoking | 44 (35.2%) | 24 (31.2%) | 20 (41.7%) | 0.22 |
| Alcohol consumption | 43 (34.4%) | 27 (35.1%) | 16 (33.3%) | 0.93 |
| Location, n (%) | 0.67 | |||
| Rectum | 94 (75.2%) | 61 (79.2%) | 33 (68.8%) | |
| Sigmoid colon | 11 (8.8%) | 6 (7.8%) | 5 (10.4%) | |
| Descending colon | 5 (4.0%) | 2 (2.6%) | 3 (6.3%) | |
| Transverse colon | 3 (2.4%) | 2 (2.6%) | 1 (2.1%) | |
| Cecum and ascending colon | 12 (9.6%) | 6 (7.8%) | 6 (12.5%) | |
| Size (cm), median (IQR) | 3.0 (2.0, 5.0) | 2.5 (1.7, 4.0) | 5.0 (3.0, 7.0) | <0.001 |
| Grade | 0.001 | |||
| G1 | 21 (16.8%) | 18 (23.4%) | 3 (6.25%) | |
| G2 | 28 (22.4%) | 22 (28.6%) | 6 (12.5%) | |
| G3 | 76 (60.8%) | 37 (48.1%) | 39 (81.3%) | |
| Differentiation | 0.001 | |||
| NET | 61 (48.8%) | 47 (61.0%) | 14 (29.2%) | |
| NEC | 64 (51.2%) | 30 (39.0%) | 34 (70.8%) | |
| Synaptophysin, n (%) | 118 (94.4%) | 72 (93.5%) | 46 (95.8%) | >0.99 |
| Chromogranin, n (%) | 78 (67.8%) | 46 (59.7%) | 32 (66.7%) | 0.53 |
| CD56, n (%) | 0.27 | |||
| Positive | 91 (72.8%) | 63 (90.0%) | 28 (82.4%) | |
| Negative | 13 (10.4%) | 7 (10.0%) | 6 (17.6%) | |
| Unknown | 21 (16.8%) | 7 (9.1%) | 14 (29.2%) | |
| Ki-67 (%), median (IQR) | 40.0% (5.0%, 70.0%) | 10.0% (3.0%, 60.0%) | 60.0% (27.5%, 80.0%) | <0.001 |
| T stage, n (%) | 0.006 | |||
| T1, T2 | 39 (31.2%) | 31 (40.3%) | 8 (16.7%) | |
| T3, T4 | 86 (68.8%) | 46 (59.7%) | 40 (83.3%) | |
| N stage, n (%) | 0.73 | |||
| N0 | 20 (16.0%) | 13 (16.9%) | 7 (14.6%) | |
| N1 | 105 (84.0%) | 64 (83.1%) | 41 (85.4%) | |
| M stage, n (%) | 0.18 | |||
| M0 | 77 (61.6%) | 51 (66.2%) | 26 (54.2%) | |
| M1 | 48 (38.4%) | 26 (33.8%) | 22 (45.8%) | |
| TNM stage, n (%) | 0.40 | |||
| II | 15 (12.0%) | 10 (13.0%) | 5 (10.4%) | |
| III | 62 (49.6%) | 41 (53.2%) | 21 (43.8%) | |
| IV | 48 (38.4%) | 26 (33.8%) | 22 (45.8%) | |
| EMVI, n (%) | 0.11 | |||
| Positive | 51 (40.8%) | 30 (48.4%) | 21 (65.6%) | |
| Negative | 43 (34.4%) | 32 (51.6%) | 11 (34.4%) | |
| Unknown | 31 (24.8%) | 15 (19.5%) | 16 (33.3%) | |
| PNI, n (%) | 0.67 | |||
| Positive | 41 (32.8%) | 28 (45.2%) | 13 (40.6%) | |
| Negative | 53 (42.4%) | 34 (54.8%) | 19 (59.4%) | |
| Unknown | 31 (24.8%) | 15 (19.5%) | 16 (33.3%) | |
| Surgery | 101 (80.8%) | 66 (85.7%) | 35 (72.9%) | 0.08 |
| Chemotherapy | 94 (75.2%) | 56 (72.7%) | 38 (79.2%) | 0.42 |
| Radiotherapy | 21 (16.8%) | 10 (13.0%) | 11 (22.9%) | 0.15 |
Patients with unknown information were not included in the χ2 -test.
SD, standard deviation; BMI, body mass index; IQR, interquartile range; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; EMVI, extramural vascular invasion; PNI, perineural invasion.